FGFR2 and intrahepatic cholangiocarcinoma: FGFR-2 inhibitors like pemigatinib are emerging for advanced cases, but their use in recurrent ICC before surgery is rare (4).Thus, neoadjuvant therapy for cholangiocarcinoma has not yet been fully established.